{"ticker": {"uuid": "6efde503-1bff-4b2c-9181-89799e2e6e18", "symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Avalo Therapeutics (Nasdaq:AVTX) - Stock Analysis", "summary": "This Simply Wall St analysis provides a detailed look at Avalo Therapeutics (AVTX), a clinical-stage biotechnology company. It covers the company's financial health, market performance, and recent developments, including the appointment of Ron Philip to its Board of Directors and", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-15T02:11:04", "published_display": "15 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AVTX) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Avalo Therapeutics Inc. (NASDAQ: AVTX), noting weak near-term sentiment but strong mid- and long-term outlooks. It identifies a significant 89.4:1 risk-reward setup, targeting a 24.6% gain, and provides three AI-generated trading strategies: Position Trading", "url": "https://news.stocktradersdaily.com/news_release/9/AVTX_as_a_Liquidity_Pulse_for_Institutional_Tactics_071526050202_1784106122.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T01:47:46", "published_display": "15 Jul 2026 01:47", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Avalo Therapeutics (AVTX)'s Russell Index Additions and Board Refresh Mean for Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T19:58:12+00:00", "published_display": "07 Jul 2026 19:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Avalo Therapeutics stock with outperform rating By Investing.com", "summary": "Leerink has initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with an Outperform rating and a $38.00 price target. The biotechnology company, specializing in IL-1\u03b2-based therapies, is advancing its lead program, abdakibart, towards a Phase 3 trial and plans to file an I", "url": "https://m.za.investing.com/news/stock-market-news/leerink-initiates-avalo-therapeutics-stock-with-outperform-rating-93CH-4356035?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T12:10:49", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $38", "summary": "Leerink Partners has initiated coverage on Avalo Therapeutics (AVTX.US) with a Buy rating. The firm has set a target price of $38 for the company's stock. This new rating suggests a positive outlook on Avalo Therapeutics' future performance from Leerink Partners.", "url": "https://www.moomoo.com/news/post/72531850/leerink-partners-initiates-avalo-therapeutics-avtxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-07T11:41:00", "published_display": "07 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum", "summary": "Avalo Therapeutics, a clinical-stage biotechnology company, announced that its management will host one-on-one investor meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The company focuses on developing therapeutics targeting the IL-1\u03b2 pathway for ", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum/2379711", "source_name": "The Manila Times", "published_at": "2026-07-07T11:01:18", "published_display": "07 Jul 2026 11:01", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics sets one-on-one investor meetings at Leerink Forum", "summary": "Avalo Therapeutics (Nasdaq: AVTX) announced it will participate in the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. Management plans to host one-on-one investor meetings to discuss the company's focus on developing therapeutics targeting the IL-1\u03b2 pathway for ", "url": "https://www.stocktitan.net/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-l9olvrofesku.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:00:18", "published_display": "07 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Avalo Therapeutics stock with outperform rating", "summary": "Leerink initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with an Outperform rating and a $38.00 price target, noting the company's lead drug abdakibart has shown positive Phase 2 data for hidradenitis suppurativa. Avalo Therapeutics, a clinical-stage biotechnology comp", "url": "https://www.investing.com/news/analyst-ratings/leerink-initiates-avalo-therapeutics-stock-with-outperform-rating-93CH-4776147", "source_name": "Investing.com", "published_at": "2026-07-06T23:41:43", "published_display": "06 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group (AVTX) reports shared control of 9,857 Avalo shares (Jul 2026)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Avalo Therapeutics, Inc. They report shared voting and shared dispositive power over 9,857 shares of Avalo common stock, re", "url": "https://www.stocktitan.net/sec-filings/AVTX/schedule-13g-a-avalo-therapeutics-inc-amended-passive-investment-disc-0a6580aa8718.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:10:48", "published_display": "06 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVTX Initiates Coverage by Leerink Partners -- Rating Set to Outperform", "summary": "Leerink Partners has initiated coverage on Avalo Therapeutics (AVTX) with an \"Outperform\" rating and a price target of $38.00. Despite this positive analyst outlook, GuruFocus indicates AVTX is significantly overvalued at $18.86 with a GF Value\u2122 of $0.03, showing a 62,783.3% over", "url": "https://www.gurufocus.com/news/8945243/avtx-initiates-coverage-by-leerink-partners-rating-set-to-outperform", "source_name": "GuruFocus", "published_at": "2026-07-06T14:10:48", "published_display": "06 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director receives fully vested options grant", "summary": "Avalo Therapeutics director Philip Ron M was granted 69 fully vested stock options on June 30, 2026, as compensation. Each option has an exercise price of $18.48 and a grant date fair value of $15.04, with an expiration date of June 30, 2036. This transaction was reported in an S", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-aadc5a8e40c5.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:39", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) CMO exercises options, sells 4,654 pre-planned shares", "summary": "Avalo Therapeutics Chief Medical Officer Mittie Doyle executed a pre-planned exercise-and-sell transaction. On June 30, 2026, Doyle sold 4,654 shares of AVTX common stock at $20.00 per share, while simultaneously exercising options to acquire the same number of shares at strike p", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-8122e815dba0.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:39", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director granted fully vested options on 1,080 shares", "summary": "Avalo Therapeutics director Rita Jain was granted fully vested stock options for 1,080 shares of AVTX common stock on June 30, 2026. The options have an exercise price of $18.48 per share and will expire on June 30, 2036. This transaction increased her direct holdings to options ", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-25835e7b0b40.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:38", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director receives grant of 1,105 stock options", "summary": "Avalo Therapeutics director Kevin Robert Lind was granted 1,105 stock options on June 30, 2026. These options, exercisable at $18.48 per share, are fully vested at grant and expire on June 30, 2036. This transaction leaves him with 1,105 options outstanding.", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-4755f88ee8f8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:38", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVTX - Avalo Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Avalo Therapeutics Inc (AVTX), including its last closing price, key financial metrics, volatility, and various performance indicators. It covers market capitalization, income, sales, earnings per share, insider and instituti", "url": "https://finviz.com/stock?t=AVTX&ta=1&p=d&ty=ocv&b=2&ov=list_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-01T09:11:30", "published_display": "01 Jul 2026 09:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Avalo Therapeutics, Inc. \u2013 NASDAQ:AVTX", "summary": "This article displays financial data for Avalo Therapeutics, Inc. (NASDAQ: AVTX), specifically its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of publication, and provides copyright and data source information for the financ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:08:59", "published_display": "01 Jul 2026 08:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Inc Actuals & Estimates (NASDAQ:AVTX)", "summary": "This article provides an overview of Avalo Therapeutics Inc. (NASDAQ: AVTX), including its current stock price, market capitalization, financial performance, and analyst forecasts. It details the company's recent stock performance, earnings, revenue, and upcoming earnings report ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-30T21:09:59", "published_display": "30 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVTX - Avalo Therapeutics Inc Latest SEC Filings", "summary": "This article provides key financial data and performance metrics for Avalo Therapeutics Inc. (AVTX). It includes details on market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various profitability ratios, alongside recent stock performance ", "url": "https://finviz.com/stock?t=AVTX&ty=lf&p=w&page=16", "source_name": "Finviz", "published_at": "2026-06-30T09:08:59", "published_display": "30 Jun 2026 09:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Avalo Therapeutics, Inc. \u2013 NASDAQ:AVTX", "summary": "This article provides the \"Price to sales forward\" metric for Avalo Therapeutics, Inc. (NASDAQ:AVTX). It is a financial data point displayed within the context of a TradingView page for the company. The specific value of the metric is not visible in the provided text, but the cat", "url": "https://www.tradingview.com/symbols/NASDAQ-AVTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:41:28", "published_display": "30 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxObTE1Y0Y5WWYzNFoxekN0Ny1Mc3NIRk1lOXAyeHQwRHVwMm5OOUxQN0pHejRqLXBrMHV4aDNSLVJlT29qV2tGN2dPN0N3R0o4TVJvbTJ4SXZwX1RvVjFxS0JvQXBUSmRuaVJlQjREQmZKUk1sQzZiYVdDQ015UU8tX25PbHFuX1hBaEd1NGVlQmVKdV9YUXdsWg?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 3000E Growth Benchmark", "summary": "Avalo Therapeutics, Inc. (NasdaqCM: AVTX) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company focuses on immune dysregulation treatments, with lead asset AVTX-009 targeting inflammatory diseases. Analyst consensus on the stock is \"BUY\" w", "url": "https://www.marketscreener.com/news/avalo-therapeutics-inc-nasdaqcm-avtx-added-to-russell-3000e-growth-benchmark-ce7f5fdeda8bf722", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:10:28", "published_display": "29 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Appoints Ron Philip to Board of Directors", "summary": "Avalo Therapeutics, a clinical-stage biotechnology company, announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings over 30 years of biopharmaceutical leadership and commercial expertise, which will be invaluable as Avalo advances its lead asset, abda", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AVTX-Q/pressreleases/2599289/avalo-therapeutics-appoints-ron-philip-to-board-of-directors/", "source_name": "The Globe and Mail", "published_at": "2026-06-28T00:39:56", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes", "summary": "Avalo Therapeutics, Inc. is set to be included in the Russell 2000 and Russell 3000 Indexes, a move that could increase its visibility and liquidity among investors. The company, a clinical-stage biotechnology firm, focuses on treatments for immune dysregulation with lead asset A", "url": "https://www.marketscreener.com/news/avalo-therapeutics-to-join-russell-2000-russell-3000-indexes-ce7f5fd9dd8ef62d", "source_name": "marketscreener.com", "published_at": "2026-06-26T11:40:24", "published_display": "26 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Joins Russell 2000 and 3000 Indices", "summary": "Avalo Therapeutics Inc (AVTX) has been included in both the Russell 2000 and Russell 3000 Indices, a move that could enhance visibility and liquidity. Despite this milestone and a recent public offering, the company faces significant challenges highlighted by a low GF Score of 23", "url": "https://www.gurufocus.com/news/8934103/avalo-therapeutics-avtx-joins-russell-2000-and-3000-indices", "source_name": "GuruFocus", "published_at": "2026-06-26T11:40:24", "published_display": "26 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Avalo Therapeutics (Nasdaq: AVTX) announced its inclusion in the small-cap Russell 2000\u00ae Index and the broad-market Russell 3000\u00ae Index, effective after the U.S. equity markets close on June 26, 2026. These indexes are widely used benchmarks by investment managers. The company is", "url": "https://www.globenewswire.com/news-release/2026/06/26/3318131/0/en/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T10:40:23", "published_display": "26 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) CMO trades 1,450 shares in 10b5-1 exercise-and-sell", "summary": "Avalo Therapeutics' Chief Medical Officer, Doyle Mittie, executed an exercise-and-sell transaction involving 1,450 shares of company stock. Mittie exercised options at $8.04 per share and simultaneously sold the same number of shares at $18.00 per share. These transactions were m", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-8e136b5a2ba7.html", "source_name": "Stock Titan", "published_at": "2026-06-26T08:41:29", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike", "summary": "Avalo Therapeutics director Philip Ron was granted 40,200 stock options at an exercise price of $17.83 per share. These options, which vest in three annual installments and expire on June 23, 2036, are a common form of equity compensation aimed at aligning board members' interest", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-dd4b1e2d729a.html", "source_name": "Stock Titan", "published_at": "2026-06-26T07:40:52", "published_display": "26 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPaEZzYjBXbEdQaWRkbE16TG1FaTdlQ08yZFYwbW9wbWhvS09IWlI2a0lxWkVjejBWelZHLVc3ZDdzM2ZXaTFvY0dkcDQtWlpzdVNlSUljTExtZHluYVBPa0t1ODdLU3lYSmhYODIyVUw4dEh4dnNZVmVaa0VUVDZ6NHJ2dVRBR2REdGswVU85cG1iNXBTR3hVYzRURko?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Plans IND Application for AVTX-010 in H1 2027", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/avalo-therapeutics-plans-ind-application-131925464.html", "source_name": "MT Newswires", "published_at": "2026-06-16T13:19:25+00:00", "published_display": "16 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1\u03b2 Antibody", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/avalo-therapeutics-expands-pipeline-avtx-110000212.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo develops longer-lasting antibody to enable less frequent dosing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNE55YTc5Y2J3eXZlQ1BiUnhvVlVGdUFHU1RrQjBMSnBMNjdaSUZtRE83bWs3bzlEdFVzS3EzQVZDUUtUTWxTZW5uVU1NQzh1NGJuaUotOVdXT3pUMWtiZzQtcUhEUm5GWmY0TUZwMVh1NldqbVB6dmdzcWZYbnY2azI3T1IwUHFzNV8ycXpwamxQT2RVbEpKYkwzTXlyN2VOdl9lNjA3TUY0OWlYWjA1clJlV0o2T0JQdzVaWlpQWTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOVW53VnpyR0haanVPM1lNc29ILXk5aGJxSjZfYVZQMUFwV19jYTU2eHNGWGdVRkdDOFYzNDBDR1NJWTItcGJ5UkJyUDFKT2p4emFhUlBYaUljcDdQS19tcW1nbmJCN3RnUHNCdk9Wb1d2QXFxTEo5d3F1X3J4OEZSSi1QbTM2cXNRdGZicks2aElpTDJST2Y4U05hUDl6endqZml4Q3Q5anRsYmhXMjlCdnFOSlhOSG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVDV1QUpEcV9jdnMxNkpVSTFrY3ZvcF9RVFJNeUdHSERkWmJpY2xWMFNmbEVFNEFZc0FkdllUSjFWcWNrdEUtSlFzcXhHMFYwUkJqeEhfREh6MW4tczZVcVA0Z0VkZXQzWnJMS3c4cHN1WjJfTG80aGpkeXhvbXRPUk1HYldMbGVjR3FCSjRWRUtKZFYyXzctUjRFTTdwN3drMU5lb2ZGR2lOcWRRcmREVzJKdVhtdkQxZUFjLUZUMnowYkRKQ2JDSm8ybw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxPbVRTUm1LTlE2VWNGYnBVei04clJVb094dzZNakxBT3dHRmYtSTdCY3o0TkV3eWdaMGpJRmx1RTQ3aHY5SUx4RDc5ZWRLSVlsSFk2ZkZiVDduS1QweEVwaHNQZ2d6OW84cWhfbzBsOTh0OHhLajZ5eWhKZS1Rd3Q3OUlDZm5HTHJSVngxMGhyekh3RGdjQWYyMVJMUVJuM0t2M3cyajNXdHhpeThLeVNpRGJIWFlJRDNvb1ltR0t1eF9RZ09Sa21kaGxmUGo0anZ0eXlFTW1FLVFLWDhrZTcyRjlkWWtVaGdUQ0htVlpCMjVPVVJsUkE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FMR (AVTX) holds 2.88M shares of Avalo Therapeutics \u2014 12.6% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRjVMUXFqZVJVdlNWeEl1QzZMd1RkNk9wTWVQaVhmdHlDSm9lcXp6V2pONXMxRl9QY3haeXhTWTRQeU1qN21EVGQwY1FKZU41dW5YLV92U1JmT2NiekZwa0NDR085SVAtTUNTbGNERHJyVDV4ZnlOTGk3YjAyYnpKR2prbHJWd3pJbzNqbXlMMXY3ajFQcVdCOXVzVl9YR05yUXEzZTBFbGxEMzRWSWdoZGI4OEYwWWZmZVdRUmVmZkFINldlT1R5QVVZRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo's skin disease drug beat placebo in Phase 2, heads to Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNSnpTUjZHUDR4dy1NaS1SbjhGZHA5dTNMQVpsd0dPcU40S3dIX05QUzdFNEhKdHAwZEcyWER5RDlWQVV0cTE1WXUtWDBHcXFqbW03ckFDVnBpV1lNNDZUY1R5elM1UW16a0RGSnRYdlRYaWE2UlNGOE1rUDRCYjVPM052Q2xjdXVMUzY3ak9YbTRVOHpqQkNoazJkekJVNEtuME43Vk1mM0R3cHJ0NVNGSmMyUk8zRUtjSnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong Phase 2 HS data for abdakibart boosts Avalo Therapeutics (NASDAQ: AVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQLTZsdlMwVTNibTltSWRtX0dfMjd6VzBFWVJSdlE2SGRSZERHV1hJdld2LVJTdzRONG9vVHZ0ZW1PZURhbVV2QXFTdUw0d0dKUXp2WnF0LTYzTjdqeDNyeDhNN0VyLWtvRThqa2d3QnRWZXZnMV9qUkR1Skpmd0JqTGZ4dzZnb0xmTHlRV0xjMU4yQnptdWlYWlpjVEJNV3VCaURWZUtDUzlvOXdxNmlBLQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo launches stock sale to fund Phase 3 abdakibart work", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObjR3ZWhaWUNHcFVpYy1rdm1LcnBDODdaaGpVREwxamZWbmxsR2xyNUotOExOeGR0cGN6REFGNWJPclNsV294S21XTnk1MlJycjVnWlBrS1FOVVdSa3FDME5LUEg5OWlaUDZfWjZkWmE1dzllWVdfa0NuTF90ZDFUblQ2ZWprMS1kS2ZMZmN4aVdqNjhRNDJnVjkxREQ5Z2lzbkF1SHdKazNxQXlnZzJWWlZERWk1cUUycFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOcnpITURBNU5BZ2JfN2ZLZGt3MlZzc3RjVWJBYlRJalNvNGVsampUemR0ZmtIWHQyM2FLTUpXUElybVBPMnBXeDhmTDdrcGV1alpfOXFGeGc1YXkwX1hlREo0OEZCUFA5ZnV4NGtudWkxSXcyVHVnVGlIOVNOOGEwZGwwZUdISmEwRm5OcGtFYkFWbmZ1ampvcWtYeGJrTXF2QWJjWXVyQjlpcUQ5MzVOT3BvOHpDSm5MOUduNWNCaXFIal9OWU9pMWZrUVdIY2dxeklwSDROcmRub1N1eFdsVDFxanhBLWctMzdVUUhxVHREN3huN1Q2Ug?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo prices $375M sale to fund drug development through Phase 3 data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNc0VfNTdYcEpNWmFKOUk1WFRuc29EU1FWZ3NrWVhSMDVINTRxNVdvUW5oejh6ZUI4RVgzT0Nna2V0c2xVZW1rbGFOWlBJSG14cS02NzlDZ0RtRFRWTUJwWkZvVERjc0NjTktkdkZfRVU5QXhFNnpvdFZuOFA0Wlc1U2dYaHZycXNDeDVGbkppVFQ0WWdwZVh0Q3JvUkUtWFhmV0VaUjBRd2JEc0RwYWdkdEltNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQkJ3SmRwN0dIVGg1Uy0yc1BvV1Z5cHhoZkR1YWNTNkJFcTNBZmFOclNEN1JDWHNvTnhBNTdKanFzMVJicXc0SHVmVmllQVZuM0NjVWhOWUJiQVZ2eGlFajY1eWlPZEF6NlZCNHVpRm52bmdabXB3UUhzWmlGYmJlWm96S0t1djA3c3VPQ3R3OURQVTJMaFQ5ZHdubGk0VXk1UGZHOWJTWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "65,800-share Form 144 filed by AVTX (NASDAQ: AVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNeGdQZzQyXzVzVmhEN09rVkNQVjVDM203WHR4b0ZGSE84NFRERUZGTXlyb0RiQWY3cU5zN0Q4bTN0V2Zsempoblp4RlNiVXlnSENxeXZpTGVEZ0FBNnJDTG16cjVoakYxYUFqYVZKcTZLeTU4Mi1icWFRUGRKdEJ5clNMZzdvRUxpamVzTTFkamgyWk5Pa3Y4WEFGdENHWjJI?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOcGdsY25SeHQxU0xZaVNJQ1E4cHd5VzBNUmpCSDQwV09jZFN2enlsM1labzhYenZwUG8taU5tUU1jRTJxUnF6Q19HUXlXV2Z2NUdDQWdjVVgzeXItbmVyTkRXT0pZSmlydGVfME5DU0YyUkFIbDlkdzR4YVlBTk01MzhaUW9LNVNWOFQ4STBpb3BTRThxcHZRQV9QUmloWkdOWE9rZkd0VXlXQWtnRGNGeDRvSnlzaXhCTUlRZUFYTWJaU0E0cWdJT1k4OFoxLVhablJ5TFRuMmM2SmtLWlBuTFEwYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNcnVMNFI3VEtZTS1JS01LbmtNRzFkc0RKMnRQbHVyNWk3LTBaTFd4azdCUDNYQjh5STd3RzZDZ0dRa2pWRjdfUnpuUVVxekdBNlQ0UzNNMFgwX2Zqcm9YVTZmdXpnWEFDUU11RTItV1RseXZWb2tTUG1aOS1IUkFJc0ZBOUMxZk5pbTd1UnBZVWhGV0J4NDlFdE9jcXdFYjd3X2J0RlVheXVZNmM3WkVPVmZHQlM5UFRBT3BRa0J1NEg2b2g4TTEyd3Ixb2txYXUwSTVLSi1uMlhzb1hoWUZJeE03T3pxc2_SAewBQVVfeXFMT3QwN0pjU3d5S0Qwd3hEWERNanIyXzN5Vm5RYjd1Zk03Mm9ySXo1Y2RFRVpzYUNEWm8wWlVodUdSSkN0cUdWYndQWUFGVFAxRHR6d3oxZVZEM3B0SkozT29jc1pXczRtVFhMRW1jV2JvdE5kZWR6REdZTGx6Z3RrcTkwQ3lVU1VDdG5JbnpQTkhFVm5zeUtSazl1d2xqLWg1bzd1amI3a2lYSHVhSDFEZ1BweVR2NUhkZVJ0NG10Wm5RYUZURlJMYm4wS0tSZ2RZeWhEWF9GS2NtVlpIeU5kUWN2QU91SDA3bUdGNDM?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5GOHdsOFgtMk9DTm81ci1reWhoejFxSlpURl9HQkQ3SmlIU3N0T3hvWEZtWDNxUmdYS25UWVRKMGNIdmZQWDIyc2Z6NXZ4X0RUcmhR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:28:11+00:00", "published_display": "25 Apr 2025 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1NMlltMDhLdHRzU1d1cmNBOUd6X3Z3WFJidEs4OVBDeWk4ZEk0dWYyNHAwcGdHd05KdlV1WTBjZTNRYk9PZVk3UGJidmNhUElVNmRqQm9oX2daZWsyaUpVRWZhS0xKZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:30:05+00:00", "published_display": "11 May 2024 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Avalo Therapeutics (Nasdaq:AVTX) - Stock Analysis", "summary": "This Simply Wall St analysis provides a detailed look at Avalo Therapeutics (AVTX), a clinical-stage biotechnology company. It covers the company's financial health, market performance, and recent developments, including the appointment of Ron Philip to its Board of Directors and", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-15T02:11:04", "published_display": "15 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AVTX) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Avalo Therapeutics Inc. (NASDAQ: AVTX), noting weak near-term sentiment but strong mid- and long-term outlooks. It identifies a significant 89.4:1 risk-reward setup, targeting a 24.6% gain, and provides three AI-generated trading strategies: Position Trading", "url": "https://news.stocktradersdaily.com/news_release/9/AVTX_as_a_Liquidity_Pulse_for_Institutional_Tactics_071526050202_1784106122.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T01:47:46", "published_display": "15 Jul 2026 01:47", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Avalo Therapeutics (AVTX)'s Russell Index Additions and Board Refresh Mean for Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T19:58:12+00:00", "published_display": "07 Jul 2026 19:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Avalo Therapeutics stock with outperform rating By Investing.com", "summary": "Leerink has initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with an Outperform rating and a $38.00 price target. The biotechnology company, specializing in IL-1\u03b2-based therapies, is advancing its lead program, abdakibart, towards a Phase 3 trial and plans to file an I", "url": "https://m.za.investing.com/news/stock-market-news/leerink-initiates-avalo-therapeutics-stock-with-outperform-rating-93CH-4356035?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T12:10:49", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $38", "summary": "Leerink Partners has initiated coverage on Avalo Therapeutics (AVTX.US) with a Buy rating. The firm has set a target price of $38 for the company's stock. This new rating suggests a positive outlook on Avalo Therapeutics' future performance from Leerink Partners.", "url": "https://www.moomoo.com/news/post/72531850/leerink-partners-initiates-avalo-therapeutics-avtxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-07T11:41:00", "published_display": "07 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum", "summary": "Avalo Therapeutics, a clinical-stage biotechnology company, announced that its management will host one-on-one investor meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The company focuses on developing therapeutics targeting the IL-1\u03b2 pathway for ", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum/2379711", "source_name": "The Manila Times", "published_at": "2026-07-07T11:01:18", "published_display": "07 Jul 2026 11:01", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics sets one-on-one investor meetings at Leerink Forum", "summary": "Avalo Therapeutics (Nasdaq: AVTX) announced it will participate in the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. Management plans to host one-on-one investor meetings to discuss the company's focus on developing therapeutics targeting the IL-1\u03b2 pathway for ", "url": "https://www.stocktitan.net/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-l9olvrofesku.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:00:18", "published_display": "07 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Avalo Therapeutics stock with outperform rating", "summary": "Leerink initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with an Outperform rating and a $38.00 price target, noting the company's lead drug abdakibart has shown positive Phase 2 data for hidradenitis suppurativa. Avalo Therapeutics, a clinical-stage biotechnology comp", "url": "https://www.investing.com/news/analyst-ratings/leerink-initiates-avalo-therapeutics-stock-with-outperform-rating-93CH-4776147", "source_name": "Investing.com", "published_at": "2026-07-06T23:41:43", "published_display": "06 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group (AVTX) reports shared control of 9,857 Avalo shares (Jul 2026)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Avalo Therapeutics, Inc. They report shared voting and shared dispositive power over 9,857 shares of Avalo common stock, re", "url": "https://www.stocktitan.net/sec-filings/AVTX/schedule-13g-a-avalo-therapeutics-inc-amended-passive-investment-disc-0a6580aa8718.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:10:48", "published_display": "06 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVTX Initiates Coverage by Leerink Partners -- Rating Set to Outperform", "summary": "Leerink Partners has initiated coverage on Avalo Therapeutics (AVTX) with an \"Outperform\" rating and a price target of $38.00. Despite this positive analyst outlook, GuruFocus indicates AVTX is significantly overvalued at $18.86 with a GF Value\u2122 of $0.03, showing a 62,783.3% over", "url": "https://www.gurufocus.com/news/8945243/avtx-initiates-coverage-by-leerink-partners-rating-set-to-outperform", "source_name": "GuruFocus", "published_at": "2026-07-06T14:10:48", "published_display": "06 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director receives fully vested options grant", "summary": "Avalo Therapeutics director Philip Ron M was granted 69 fully vested stock options on June 30, 2026, as compensation. Each option has an exercise price of $18.48 and a grant date fair value of $15.04, with an expiration date of June 30, 2036. This transaction was reported in an S", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-aadc5a8e40c5.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:39", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) CMO exercises options, sells 4,654 pre-planned shares", "summary": "Avalo Therapeutics Chief Medical Officer Mittie Doyle executed a pre-planned exercise-and-sell transaction. On June 30, 2026, Doyle sold 4,654 shares of AVTX common stock at $20.00 per share, while simultaneously exercising options to acquire the same number of shares at strike p", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-8122e815dba0.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:39", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director granted fully vested options on 1,080 shares", "summary": "Avalo Therapeutics director Rita Jain was granted fully vested stock options for 1,080 shares of AVTX common stock on June 30, 2026. The options have an exercise price of $18.48 per share and will expire on June 30, 2036. This transaction increased her direct holdings to options ", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-25835e7b0b40.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:38", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director receives grant of 1,105 stock options", "summary": "Avalo Therapeutics director Kevin Robert Lind was granted 1,105 stock options on June 30, 2026. These options, exercisable at $18.48 per share, are fully vested at grant and expire on June 30, 2036. This transaction leaves him with 1,105 options outstanding.", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-4755f88ee8f8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:38", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVTX - Avalo Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Avalo Therapeutics Inc (AVTX), including its last closing price, key financial metrics, volatility, and various performance indicators. It covers market capitalization, income, sales, earnings per share, insider and instituti", "url": "https://finviz.com/stock?t=AVTX&ta=1&p=d&ty=ocv&b=2&ov=list_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-01T09:11:30", "published_display": "01 Jul 2026 09:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Avalo Therapeutics, Inc. \u2013 NASDAQ:AVTX", "summary": "This article displays financial data for Avalo Therapeutics, Inc. (NASDAQ: AVTX), specifically its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of publication, and provides copyright and data source information for the financ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:08:59", "published_display": "01 Jul 2026 08:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Inc Actuals & Estimates (NASDAQ:AVTX)", "summary": "This article provides an overview of Avalo Therapeutics Inc. (NASDAQ: AVTX), including its current stock price, market capitalization, financial performance, and analyst forecasts. It details the company's recent stock performance, earnings, revenue, and upcoming earnings report ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-30T21:09:59", "published_display": "30 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVTX - Avalo Therapeutics Inc Latest SEC Filings", "summary": "This article provides key financial data and performance metrics for Avalo Therapeutics Inc. (AVTX). It includes details on market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various profitability ratios, alongside recent stock performance ", "url": "https://finviz.com/stock?t=AVTX&ty=lf&p=w&page=16", "source_name": "Finviz", "published_at": "2026-06-30T09:08:59", "published_display": "30 Jun 2026 09:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Avalo Therapeutics, Inc. \u2013 NASDAQ:AVTX", "summary": "This article provides the \"Price to sales forward\" metric for Avalo Therapeutics, Inc. (NASDAQ:AVTX). It is a financial data point displayed within the context of a TradingView page for the company. The specific value of the metric is not visible in the provided text, but the cat", "url": "https://www.tradingview.com/symbols/NASDAQ-AVTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:41:28", "published_display": "30 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxObTE1Y0Y5WWYzNFoxekN0Ny1Mc3NIRk1lOXAyeHQwRHVwMm5OOUxQN0pHejRqLXBrMHV4aDNSLVJlT29qV2tGN2dPN0N3R0o4TVJvbTJ4SXZwX1RvVjFxS0JvQXBUSmRuaVJlQjREQmZKUk1sQzZiYVdDQ015UU8tX25PbHFuX1hBaEd1NGVlQmVKdV9YUXdsWg?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 3000E Growth Benchmark", "summary": "Avalo Therapeutics, Inc. (NasdaqCM: AVTX) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company focuses on immune dysregulation treatments, with lead asset AVTX-009 targeting inflammatory diseases. Analyst consensus on the stock is \"BUY\" w", "url": "https://www.marketscreener.com/news/avalo-therapeutics-inc-nasdaqcm-avtx-added-to-russell-3000e-growth-benchmark-ce7f5fdeda8bf722", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:10:28", "published_display": "29 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Appoints Ron Philip to Board of Directors", "summary": "Avalo Therapeutics, a clinical-stage biotechnology company, announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings over 30 years of biopharmaceutical leadership and commercial expertise, which will be invaluable as Avalo advances its lead asset, abda", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AVTX-Q/pressreleases/2599289/avalo-therapeutics-appoints-ron-philip-to-board-of-directors/", "source_name": "The Globe and Mail", "published_at": "2026-06-28T00:39:56", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes", "summary": "Avalo Therapeutics, Inc. is set to be included in the Russell 2000 and Russell 3000 Indexes, a move that could increase its visibility and liquidity among investors. The company, a clinical-stage biotechnology firm, focuses on treatments for immune dysregulation with lead asset A", "url": "https://www.marketscreener.com/news/avalo-therapeutics-to-join-russell-2000-russell-3000-indexes-ce7f5fd9dd8ef62d", "source_name": "marketscreener.com", "published_at": "2026-06-26T11:40:24", "published_display": "26 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Joins Russell 2000 and 3000 Indices", "summary": "Avalo Therapeutics Inc (AVTX) has been included in both the Russell 2000 and Russell 3000 Indices, a move that could enhance visibility and liquidity. Despite this milestone and a recent public offering, the company faces significant challenges highlighted by a low GF Score of 23", "url": "https://www.gurufocus.com/news/8934103/avalo-therapeutics-avtx-joins-russell-2000-and-3000-indices", "source_name": "GuruFocus", "published_at": "2026-06-26T11:40:24", "published_display": "26 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Avalo Therapeutics (Nasdaq: AVTX) announced its inclusion in the small-cap Russell 2000\u00ae Index and the broad-market Russell 3000\u00ae Index, effective after the U.S. equity markets close on June 26, 2026. These indexes are widely used benchmarks by investment managers. The company is", "url": "https://www.globenewswire.com/news-release/2026/06/26/3318131/0/en/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T10:40:23", "published_display": "26 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) CMO trades 1,450 shares in 10b5-1 exercise-and-sell", "summary": "Avalo Therapeutics' Chief Medical Officer, Doyle Mittie, executed an exercise-and-sell transaction involving 1,450 shares of company stock. Mittie exercised options at $8.04 per share and simultaneously sold the same number of shares at $18.00 per share. These transactions were m", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-8e136b5a2ba7.html", "source_name": "Stock Titan", "published_at": "2026-06-26T08:41:29", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike", "summary": "Avalo Therapeutics director Philip Ron was granted 40,200 stock options at an exercise price of $17.83 per share. These options, which vest in three annual installments and expire on June 23, 2036, are a common form of equity compensation aimed at aligning board members' interest", "url": "https://www.stocktitan.net/sec-filings/AVTX/form-4-avalo-therapeutics-inc-insider-trading-activity-dd4b1e2d729a.html", "source_name": "Stock Titan", "published_at": "2026-06-26T07:40:52", "published_display": "26 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPaEZzYjBXbEdQaWRkbE16TG1FaTdlQ08yZFYwbW9wbWhvS09IWlI2a0lxWkVjejBWelZHLVc3ZDdzM2ZXaTFvY0dkcDQtWlpzdVNlSUljTExtZHluYVBPa0t1ODdLU3lYSmhYODIyVUw4dEh4dnNZVmVaa0VUVDZ6NHJ2dVRBR2REdGswVU85cG1iNXBTR3hVYzRURko?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Plans IND Application for AVTX-010 in H1 2027", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/avalo-therapeutics-plans-ind-application-131925464.html", "source_name": "MT Newswires", "published_at": "2026-06-16T13:19:25+00:00", "published_display": "16 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1\u03b2 Antibody", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/avalo-therapeutics-expands-pipeline-avtx-110000212.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo develops longer-lasting antibody to enable less frequent dosing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNE55YTc5Y2J3eXZlQ1BiUnhvVlVGdUFHU1RrQjBMSnBMNjdaSUZtRE83bWs3bzlEdFVzS3EzQVZDUUtUTWxTZW5uVU1NQzh1NGJuaUotOVdXT3pUMWtiZzQtcUhEUm5GWmY0TUZwMVh1NldqbVB6dmdzcWZYbnY2azI3T1IwUHFzNV8ycXpwamxQT2RVbEpKYkwzTXlyN2VOdl9lNjA3TUY0OWlYWjA1clJlV0o2T0JQdzVaWlpQWTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOVW53VnpyR0haanVPM1lNc29ILXk5aGJxSjZfYVZQMUFwV19jYTU2eHNGWGdVRkdDOFYzNDBDR1NJWTItcGJ5UkJyUDFKT2p4emFhUlBYaUljcDdQS19tcW1nbmJCN3RnUHNCdk9Wb1d2QXFxTEo5d3F1X3J4OEZSSi1QbTM2cXNRdGZicks2aElpTDJST2Y4U05hUDl6endqZml4Q3Q5anRsYmhXMjlCdnFOSlhOSG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVDV1QUpEcV9jdnMxNkpVSTFrY3ZvcF9RVFJNeUdHSERkWmJpY2xWMFNmbEVFNEFZc0FkdllUSjFWcWNrdEUtSlFzcXhHMFYwUkJqeEhfREh6MW4tczZVcVA0Z0VkZXQzWnJMS3c4cHN1WjJfTG80aGpkeXhvbXRPUk1HYldMbGVjR3FCSjRWRUtKZFYyXzctUjRFTTdwN3drMU5lb2ZGR2lOcWRRcmREVzJKdVhtdkQxZUFjLUZUMnowYkRKQ2JDSm8ybw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxPbVRTUm1LTlE2VWNGYnBVei04clJVb094dzZNakxBT3dHRmYtSTdCY3o0TkV3eWdaMGpJRmx1RTQ3aHY5SUx4RDc5ZWRLSVlsSFk2ZkZiVDduS1QweEVwaHNQZ2d6OW84cWhfbzBsOTh0OHhLajZ5eWhKZS1Rd3Q3OUlDZm5HTHJSVngxMGhyekh3RGdjQWYyMVJMUVJuM0t2M3cyajNXdHhpeThLeVNpRGJIWFlJRDNvb1ltR0t1eF9RZ09Sa21kaGxmUGo0anZ0eXlFTW1FLVFLWDhrZTcyRjlkWWtVaGdUQ0htVlpCMjVPVVJsUkE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR (AVTX) holds 2.88M shares of Avalo Therapeutics \u2014 12.6% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRjVMUXFqZVJVdlNWeEl1QzZMd1RkNk9wTWVQaVhmdHlDSm9lcXp6V2pONXMxRl9QY3haeXhTWTRQeU1qN21EVGQwY1FKZU41dW5YLV92U1JmT2NiekZwa0NDR085SVAtTUNTbGNERHJyVDV4ZnlOTGk3YjAyYnpKR2prbHJWd3pJbzNqbXlMMXY3ajFQcVdCOXVzVl9YR05yUXEzZTBFbGxEMzRWSWdoZGI4OEYwWWZmZVdRUmVmZkFINldlT1R5QVVZRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo's skin disease drug beat placebo in Phase 2, heads to Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNSnpTUjZHUDR4dy1NaS1SbjhGZHA5dTNMQVpsd0dPcU40S3dIX05QUzdFNEhKdHAwZEcyWER5RDlWQVV0cTE1WXUtWDBHcXFqbW03ckFDVnBpV1lNNDZUY1R5elM1UW16a0RGSnRYdlRYaWE2UlNGOE1rUDRCYjVPM052Q2xjdXVMUzY3ak9YbTRVOHpqQkNoazJkekJVNEtuME43Vk1mM0R3cHJ0NVNGSmMyUk8zRUtjSnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong Phase 2 HS data for abdakibart boosts Avalo Therapeutics (NASDAQ: AVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQLTZsdlMwVTNibTltSWRtX0dfMjd6VzBFWVJSdlE2SGRSZERHV1hJdld2LVJTdzRONG9vVHZ0ZW1PZURhbVV2QXFTdUw0d0dKUXp2WnF0LTYzTjdqeDNyeDhNN0VyLWtvRThqa2d3QnRWZXZnMV9qUkR1Skpmd0JqTGZ4dzZnb0xmTHlRV0xjMU4yQnptdWlYWlpjVEJNV3VCaURWZUtDUzlvOXdxNmlBLQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo launches stock sale to fund Phase 3 abdakibart work", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObjR3ZWhaWUNHcFVpYy1rdm1LcnBDODdaaGpVREwxamZWbmxsR2xyNUotOExOeGR0cGN6REFGNWJPclNsV294S21XTnk1MlJycjVnWlBrS1FOVVdSa3FDME5LUEg5OWlaUDZfWjZkWmE1dzllWVdfa0NuTF90ZDFUblQ2ZWprMS1kS2ZMZmN4aVdqNjhRNDJnVjkxREQ5Z2lzbkF1SHdKazNxQXlnZzJWWlZERWk1cUUycFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOcnpITURBNU5BZ2JfN2ZLZGt3MlZzc3RjVWJBYlRJalNvNGVsampUemR0ZmtIWHQyM2FLTUpXUElybVBPMnBXeDhmTDdrcGV1alpfOXFGeGc1YXkwX1hlREo0OEZCUFA5ZnV4NGtudWkxSXcyVHVnVGlIOVNOOGEwZGwwZUdISmEwRm5OcGtFYkFWbmZ1ampvcWtYeGJrTXF2QWJjWXVyQjlpcUQ5MzVOT3BvOHpDSm5MOUduNWNCaXFIal9OWU9pMWZrUVdIY2dxeklwSDROcmRub1N1eFdsVDFxanhBLWctMzdVUUhxVHREN3huN1Q2Ug?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo prices $375M sale to fund drug development through Phase 3 data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNc0VfNTdYcEpNWmFKOUk1WFRuc29EU1FWZ3NrWVhSMDVINTRxNVdvUW5oejh6ZUI4RVgzT0Nna2V0c2xVZW1rbGFOWlBJSG14cS02NzlDZ0RtRFRWTUJwWkZvVERjc0NjTktkdkZfRVU5QXhFNnpvdFZuOFA0Wlc1U2dYaHZycXNDeDVGbkppVFQ0WWdwZVh0Q3JvUkUtWFhmV0VaUjBRd2JEc0RwYWdkdEltNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQkJ3SmRwN0dIVGg1Uy0yc1BvV1Z5cHhoZkR1YWNTNkJFcTNBZmFOclNEN1JDWHNvTnhBNTdKanFzMVJicXc0SHVmVmllQVZuM0NjVWhOWUJiQVZ2eGlFajY1eWlPZEF6NlZCNHVpRm52bmdabXB3UUhzWmlGYmJlWm96S0t1djA3c3VPQ3R3OURQVTJMaFQ5ZHdubGk0VXk1UGZHOWJTWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "65,800-share Form 144 filed by AVTX (NASDAQ: AVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNeGdQZzQyXzVzVmhEN09rVkNQVjVDM203WHR4b0ZGSE84NFRERUZGTXlyb0RiQWY3cU5zN0Q4bTN0V2Zsempoblp4RlNiVXlnSENxeXZpTGVEZ0FBNnJDTG16cjVoakYxYUFqYVZKcTZLeTU4Mi1icWFRUGRKdEJ5clNMZzdvRUxpamVzTTFkamgyWk5Pa3Y4WEFGdENHWjJI?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOcGdsY25SeHQxU0xZaVNJQ1E4cHd5VzBNUmpCSDQwV09jZFN2enlsM1labzhYenZwUG8taU5tUU1jRTJxUnF6Q19HUXlXV2Z2NUdDQWdjVVgzeXItbmVyTkRXT0pZSmlydGVfME5DU0YyUkFIbDlkdzR4YVlBTk01MzhaUW9LNVNWOFQ4STBpb3BTRThxcHZRQV9QUmloWkdOWE9rZkd0VXlXQWtnRGNGeDRvSnlzaXhCTUlRZUFYTWJaU0E0cWdJT1k4OFoxLVhablJ5TFRuMmM2SmtLWlBuTFEwYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNcnVMNFI3VEtZTS1JS01LbmtNRzFkc0RKMnRQbHVyNWk3LTBaTFd4azdCUDNYQjh5STd3RzZDZ0dRa2pWRjdfUnpuUVVxekdBNlQ0UzNNMFgwX2Zqcm9YVTZmdXpnWEFDUU11RTItV1RseXZWb2tTUG1aOS1IUkFJc0ZBOUMxZk5pbTd1UnBZVWhGV0J4NDlFdE9jcXdFYjd3X2J0RlVheXVZNmM3WkVPVmZHQlM5UFRBT3BRa0J1NEg2b2g4TTEyd3Ixb2txYXUwSTVLSi1uMlhzb1hoWUZJeE03T3pxc2_SAewBQVVfeXFMT3QwN0pjU3d5S0Qwd3hEWERNanIyXzN5Vm5RYjd1Zk03Mm9ySXo1Y2RFRVpzYUNEWm8wWlVodUdSSkN0cUdWYndQWUFGVFAxRHR6d3oxZVZEM3B0SkozT29jc1pXczRtVFhMRW1jV2JvdE5kZWR6REdZTGx6Z3RrcTkwQ3lVU1VDdG5JbnpQTkhFVm5zeUtSazl1d2xqLWg1bzd1amI3a2lYSHVhSDFEZ1BweVR2NUhkZVJ0NG10Wm5RYUZURlJMYm4wS0tSZ2RZeWhEWF9GS2NtVlpIeU5kUWN2QU91SDA3bUdGNDM?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5GOHdsOFgtMk9DTm81ci1reWhoejFxSlpURl9HQkQ3SmlIU3N0T3hvWEZtWDNxUmdYS25UWVRKMGNIdmZQWDIyc2Z6NXZ4X0RUcmhR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:28:11+00:00", "published_display": "25 Apr 2025 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avalo Therapeutics (AVTX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1NMlltMDhLdHRzU1d1cmNBOUd6X3Z3WFJidEs4OVBDeWk4ZEk0dWYyNHAwcGdHd05KdlV1WTBjZTNRYk9PZVk3UGJidmNhUElVNmRqQm9oX2daZWsyaUpVRWZhS0xKZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:30:05+00:00", "published_display": "11 May 2024 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 57, "sentiment_summary": {"positive": 15, "negative": 4, "neutral": 38, "score": 54, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 15, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 19.21, "latest_week": "2026-07-10", "one_week_move": 2.0, "four_week_move": 30.1, "twelve_week_move": 33.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.452955, "market_dynamics_buy_signal": false, "relative_strength": 12.715297, "fair_value_gap": 42.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 42.9577, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.0% over one week, +30.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 18}, {"label": "Market source", "count": 8}, {"label": "simplywall.st", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "The Globe and Mail", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.0% over one week, +30.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Avalo Therapeutics (Nasdaq:AVTX) - Stock Analysis"}], "updated_at": "2026-07-17T06:46:03.501575+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}